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Introduction: Chronic obstructive pulmonary disease (COPD) constitutes a major health 
challenge in Central and Eastern European (CEE) countries. However, clinical phenotypes, 
symptom load, and treatment habits of patients with COPD in CEE countries remain largely 
unknown. This paper provides a rationale for phenotyping COPD and describes the methodol-
ogy of a large study in CEE.
Methods/design: The POPE study is an international, multicenter, observational cross-sectional 
survey of patients with COPD in CEE. Participation in the study is offered to all consecutive 
outpatients with stable COPD in 84 centers across the CEE region if they fulfill the following 
criteria: age .40 years, smoking history $10 pack-years, a confirmed diagnosis of COPD with 
postbronchodilator FEV
1
/FVC ,0.7, and absence of COPD exacerbation $4 weeks. Medical 
history, risk factors for COPD, comorbidities, lung function parameters, symptoms, and phar-
maceutical and nonpharmaceutical treatment are recorded. The POPE project is registered in 
ClinicalTrials.gov with the identifier NCT02119494.
Outcomes: The primary aim of the POPE study was to phenotype patients with COPD in a 
real-life setting within CEE countries using predefined classifications. Secondary aims of the 
study included analysis of differences in symptoms, and diagnostic and therapeutic behavior 
in participating CEE countries.
Conclusion: There is increasing acceptance toward a phenotype-driven therapeutic approach in 
COPD. The POPE study may contribute to reveal important information regarding phenotypes 
and therapy in real-life CEE.
Keywords: COPD, phenotypes, Central Europe, Eastern Europe, study, GOLD, comorbidity
Introduction
Chronic obstructive pulmonary disease (COPD) is a major cause of death worldwide 
and represents an important public health challenge.1 On the basis of multiple studies 
that have been published since the 1970s, the estimate of COPD prevalence ranges 
between 5% and 10%.2,3 According to the World Health Organization estimates, COPD 
is predicted to become the third leading cause of death by 2030, and the burden of 
COPD is projected to further increase in coming decades due to continued exposure 
to COPD risk factors and aging of the population.4–6 While the major risk factor 
is tobacco smoking, other risk factors include age, a previous history of bronchial 
asthma, genetic predisposition, and respiratory infections.7–12 In addition to these 
factors, environmental and occupational exposure to gases and particles and indoor 
biomass inhalation may also substantially contribute to the development of COPD in 
affected populations.13,14
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Although numerous studies and clinical trials regarding 
clinical presentation, diagnosis, and management of 
COPD have been recently published, very few of these 
studies have specifically focused on Central and Eastern 
Europe (CEE).15–23 However, patients with COPD in CEE 
might present with different features of the disease due to 
differences in environmental and nonenvironmental risk 
factors, age of onset of disease, comorbidities, health care 
access, and the level of reimbursement for COPD treat-
ment. Thus, the objectives of the “Phenotypes of COPD in 
Central and Eastern Europe Study” (POPE study) are to gain 
a better understanding of these patient characteristics and 
treatment patterns of patients diagnosed with COPD among 
different CEE countries. This is the first CEE, multicenter, 
investigator-initiated, collaborative project of its kind. The 
purposes of this paper are to provide an introduction to the 
study methodology and to raise awareness toward a current 
hot topic in COPD research, namely, the issue of COPD 
phenotyping.
Methods/design
Study design
The POPE study is an international, multicenter, observational 
cross-sectional survey in patients with COPD in CEE. Eleven 
CEE countries participated in the study: Austria, Bulgaria, 
Croatia, Czech Republic, Hungary, Latvia, Poland, Russia, 
Serbia, Slovakia, and Slovenia (Figure 1). The complete 
list of participating centers is listed in Table 1. A Steering 
Committee consisting of eight physicians is responsible for 
the scientific integrity of the study (Table 2). Each partici-
pating country is represented by one national leading expert, 
who coordinates the study at the national level (Table 1). 
Within each participating country, investigators selected by 
the national expert are appointed and are responsible for local 
data collection and organization of care. The first patient (FPI) 
in the database was documented in April 2014. The expected 
end of patient enrollment in all countries was July 2015.
the objectives
The primary aim of this study was to assess the prevalence 
of COPD phenotypes according to predefined criteria in an 
unselected group of consecutively examined patients with 
stable COPD in the CEE region in a real-life setting (Figure 2). 
Secondary aims of the study included analysis of differences 
in symptom load, and diagnostic and therapeutic behavior in 
patients classified into different phenotypes. As the POPE study 
will actively recruit patients with COPD due to environmental 
risk factors other than smoking, separate analysis will be 
Figure 1 Map of participating countries.
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Table 1 POPE study – participating centers
Austria
National expert Assoc Prof Arschang Valipour, MD, PhD
ludwig Boltzmann Institute, Wien
AKH linz, Department of Pulmonary Medicine
Pulmonary rehab Centre, therme Wien
Department of Internal Medicine, university Innsbruck
SKA der PV Weyer/Enns, Mühlein
Bulgaria
National expert Assoc Prof Kosta Kostov, MD, PhD
Pulmonary Diseases Clinic, Military Medical Academy, Sofia
Clinic for Pneumonology and Phisiatry, uMHAt “Dr Georgi Stranski”, Pleven
Clinic of Pulmonology, MHAt “St Marina”, Varna
Department of respiratory Diseases, Medical university, Plovdiv
Croatia
National expert Prof Neven tudoric, MD, PhD
university Hospital Dubrava, Zagreb
university Hospital Centre, Zagreb
university Hospital Centre, Split
university Hospital Centre, rijeka
Clinical Hospital, Osijek
Czech Republic
National expert Vladimir Koblizek, MD, PhD
Outpatient Department of Pneumology and Pulmonary Diagnostics, Karlovy Vary
Pneumological Outpatient Department, Mepha-Centrum, Ostrava
Pneumology Centre, teplice
Department of Pneumology, university Hospital Hradec Králové and Faculty of Medicine in Hradec Králové of the Charles 
university in Prague
Hungary
National expert Prof Attila Somfay, MD, PhD
Csongrád County Hospital for Chest Diseases, Deszk
IZO PulM Health Service ltd., Budapest
St Elizabeth Hospital Pulmonary Care Institute, Jászberény
Szarvas respiratory ltd., Szarvas
Újpest Non-Profit Health Care Services Ltd., Budapest
Elizabeth House Care Ltd., Gödöllő
Medical Institution of Dr laszlo romics Pulmonary Care, Érd
Szabolcs-Szatmár-Bereg County Hospitals and university teaching Hospital, Nyíregyháza
Baja St rókus Hospital Patient lung Care Institute, Baja
Latvia
National expert Prof Alvis Krams, MD, PhD
regional Hospital of liepaja
Kuldıˉga Hospital
SIA “BINI”, Ventspils
Health Centre talsi
Ambulatory Clinic Jelgava
Bauska Hospital
Ambulatory Clinic Dubulti, Jurmala
Privat practice Ilona uzbeka, Valka
Privat practice Dace Harasimjuka, Valmiera
Madona Hospital
Health Centre Balvi
Private practice Viktorija Vevere, rezekne
regional Hospital of Jekabpils
Pauls Stradins Clinical university Hospital, riga
riga East Clinical university Hospital, “Gailezers”, riga
riga East Clinical university Hospital, In-patient Department “Centre of tuberculosis and lung Diseases”, riga
lu MPI Institute private practice, riga
riga 1st Hospital, riga
(Continued)
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Table 1 (Continued)
Health Centre 4, ltd, riga
uniClinic, riga
Poland
National expert Assoc Prof Adam Barczyk, MD, PhD
Oddział Chorób Płuc i Niewydolności Oddychania, Kujawsko – Pomorskie, Centrum Pulmonologii w Bydgoszczy, Bydgoszcz
Katedra i Klinika Chorób Wewnętrznych, Pneumonologii i Alergologii, Samodzielny Publiczny Centralny Szpital Kliniczny, 
Warszawa
Klinika Alergologii i Pneumonologii, Uniwersyteckie Centrum Kliniczne, Szpital Gdańskiego Uniwersytetu Medycznego, Gdańsk
Oddział Chorób Płuc, Wojewódzkie Centrum Szpitalne Kotliny Jeleniogórskiej, Jelenia Góra
Katedra i Klinika Pulmonologii, Alergologii i Onkologii Pulmonologicznej, uniwersytet Medyczny im. Karola Marcinkowskiego  
w Poznaniu, Poznań
Szpital Uniwersytecki, Oddział Kliniczny Kliniki Pulmonologii, Kraków
Katedra i Klinika Pneumonologii, Śląski Uniwersytet Medyczny, Katowice
Russia
National expert Prof Kirill Zykov, MD, PhD
Pulmonology research Institute, Moscow
ufa State City Clinical Hospital 21, ufa
Clinic of Pulmonology of Scientific and Clinical Center of Interstitial and Orphan Lung Diseases, St Petersburg
State Budget Educational Institution of High Professional Education “Kazan State Medical university”, Kazan
Vladivostok Clinical Hospital #1, Vladivostok
I.M. Sechenov First Moscow State Medical university, university Hospital #1, Outpatient Department, Moscow
GBOu VPO Samara State Medical university, Samara
Moscow State university of Medicine and Dentistry named after A.I. Evdokimov, Moscow
Serbia
National expert Prof Branislava Milenkovic, MD, PhD
Clinic for Pulmonary Diseases, Clinical Centre of Serbia, Belgrade
Institute for Pulmonary Diseases and tB, Clinical Centre Vojvodina, Novi Sad
Clinic for Pulmonary Diseases, Clinical Center of Niš
Clinic for Pulmonary Diseases, Clinical Centre Kragujevac
Municipal Institute for lung Diseases and tuberculosis, Belgrade
Slovakia
National expert Prof ruzena tkacova, MD, PhD
Ambulancia pneumológie a ftizeológie Doc. MuDr Ján Plutinský, CSc, levice
Pľúcna ambulancia, Poprad
MuDr Katarína Arpášová – Dionea, s.r.o., Nové Zámky
Klinika pneumológie a ftizeológie lF SZu a uNB, Bratislava
NsP, Považská Bystrica
Zdravotné stredisko Fedinova, Bratislava
Klinika tubekulózy a respiračných chorôb JLF UK a UNM, Martin
FNsP F.D. roosevelta, Banská Bystrica
NsP Sv. Jakuba, Bardejov
Zdravotné stredisko rimava, rimavská Sobota
Slovenia
National expert Jurij Šorli, MD, PhD
Bolnišnica topolšica, topolšica
Alveola, d.o.o., Maribor
Zdravstveni dom Murska Sobota, Murska Sobota
Table 2 POPE study – Steering Committee
Steering Committee members
Austria Assoc Prof Arschang Valipour, MD, PhD
Croatia Prof Neven tudoric, MD, PhD
Czech republic Vladimir Koblizek, MD, PhD
Hungary Prof Attila Somfay, MD, PhD
Poland Assoc Prof Adam Barczyk, MD, PhD
russia Prof Kirill Zykov, MD, PhD
Slovakia Prof ruzena tkacova, MD, PhD
Spain Prof Marc Miravitlles, MD, PhD
conducted to ascertain differences with a matched cohort of 
“smokers-related” COPD. The long-term aims of the POPE 
study are to educate and raise awareness for COPD phenotypes 
among both physicians and patients to support an individual-
ized patient treatment approach in clinical practice.
Participants
All consecutive patients with COPD examined at office-based 
physician and outpatient clinics from different institutions 
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were enrolled in this study if they fulfill the following inclu-
sion criteria: age more than 40 years, confirmed diagnosis 
of COPD with postbronchodilator forced expired volume 
in 1 second/forced vital capacity (FEV
1
/FVC) ,0.7, and 
absence of exacerbation for at least 4 weeks. The rationale 
for inclusion criteria imply the following points. The pres-
ence of postbronchodilator airflow limitation among persons 
over age 40 years is the common definition of COPD cases 
used worldwide. Younger subjects with bronchial obstruc-
tion represent rather a rarity. Moreover, airflow limitation 
in people below 40 years of age may be due to other causes 
(asthma, bronchiolitis, primary ciliary dyskinesia, etc). 
Acute exacerbation of COPD has multiple negative effects 
on lung functions and respiratory symptoms (important 
parameters of our research). Therefore, we have used 4-week 
exacerbation-free interval as an elimination factor against 
bias (in term of symptoms and pulmonary functions). POPE 
study patients were divided into Group A if they have a 
smoking history equal and/or more than 10 pack-years and 
Group B if they were nonsmokers or smokers of less than 
10 pack-years with evidence of inhalation exposure to other 
risk factors. Other risk factors were also counted: workplace 
environment, frequent exposure to outdoor pollution, 
frequent exposure to indoor pollution, and cooking without 
ventilation. COPD is clearly defined as an enhanced chronic 
inflammatory response to inhaled noxious particles and/or 
gases. Accordingly, non-/low-smoking patients without the 
aforementioned predefined risk factors were excluded from 
POPE study. Patient enrollment started in April 2014 and 
continued through July 2015; thus, a relevant seasonal bias 
of recruitment was prevented.
Study protocol
The study protocol was conceived to capture all data 
routinely available for clinical phenotyping during one visit. 
The parameters selected were identified by the Steering 
Committee (Table 2) together with a panel of national 
experts. An electronic case report form (eCRF) was used 
for local data collection.
For each patient, an in-depth history was obtained, includ-
ing information on allergy and atopy, COPD symptoms 
(dyspnoea at rest/during exercise, fatigue, cough, chronic 
sputum production, purulent expectoration, and hemoptysis), 
smoking status and other respiratory risk factors, history of 
$VWKPDEHIRUHWKHDJHRI\HDUVRU3RVLWLYH%'WHVWLQODVWPRQWKVSRVLWLYHKLVWRU\RIDWRS\DQGRUDOOHUJ\
)UHTXHQWH[DFHUEDWLRQ±RUPRUHPRGHUDWHDQGVHYHUHH[DFHUEDWLRQVLQODVWPRQWKV
&KURQLFVSXWXPSURGXFWLRQPRQWKV\HDUIRURUPRUHFRQVHFXWLYH\HDUV
)UHTXHQWH[DFHUEDWRUZLWK&%
)UHTXHQWH[DFHUEDWRU
1RQH[DFHUEDWRU
$&26
<HV
<HV
<HV
1R
1R
1R
)UHTXHQWH[DFHUEDWRUZLWKRXW&%
Figure 2 Definition of phenotypes.
Abbreviations: ACOS, asthma–COPD overlap syndrome; BD, bronchodilator; CB, chronic bronchitis.
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acute respiratory events, including the number of COPD 
exacerbations with or without hospitalization, concomitant 
respiratory and nonrespiratory diseases, and assessment of 
the body composition (weight and height were routinely 
measured before spirometry, and self-reported weight loss or 
weight gain [absolute, relative rate] were registered as well). 
Comorbidities were scored using the Charlson comorbidity 
index.24 Physical examination was performed on each patient. 
Pulmonary function data were obtained using standard 
equipment according to the ATS/ERS consensus guidelines.25 
The European Community of Coal and Steel reference 
equations were used in the POPE study. Postbronchodila-
tor spirometry values for assessing COPD disease severity 
were reported in all patients (mandatory data). Furthermore, 
additional information regarding results obtained from 
bronchodilator reversibility testing, body plethysmography, 
diffusion capacity, fractional exhaled nitric oxide (FeNO), 
thoracic computed tomography, echocardiography, blood/
sputum eosinophil assessment, serum immunoglobulin (IgE) 
measurement, arterial blood gases (ABG), and hematocrit 
(HTC) were recorded, if available, and performed within the 
last 12 months. Because this is a noninterventional study, 
obtaining the aforementioned additional information was 
considered optional. Thus, the information provided in this 
context represents the true level of diagnostic investigations 
for COPD in CEE countries. Patients included were classi-
fied into the Global Initiative for chronic Obstructive Lung 
Disease (GOLD) risk classification category on the basis of 
postbronchodilator FEV
1
, history of COPD exacerbations, 
respiratory symptoms using the modified Medical Research 
Council (mMRC) dyspnea scale, and the COPD Assessment 
Test (CAT).1,26,27 With regard to CAT, total CAT score and 
all CAT subitems were separately noted. Any pharmaceuti-
cal treatment prescribed for COPD for at least 1 month was 
recorded together with medications for typical comorbidities. 
Nonpharmaceutical therapeutic options, including long-term 
oxygen therapy (LTOT), use of noninvasive ventilation, 
bronchoscopic or surgical volume reduction procedures, and/
or relevant vaccinations for individual patients were recorded 
as well. An overview of the collected data is listed in Table 3. 
Patients were stratified according to predefined phenotypes. 
The phenotypes proposed by the Steering Committee con-
sensus were consistent with a recent recommendation from 
Spain proposing four clinically defined groups (Figure 2).28 
The following simple algorithm was used to determine the 
phenotype: 1) patients with a previous diagnosis of asthma 
were considered a mixed COPD–asthma phenotype (asthma–
COPD overlap syndrome, ACOS), 2) patients with less than 
two exacerbations in the previous year were classified as 
nonexacerbators, 3) exacerbators with self-reported chronic 
cough and expectoration for more than 3 months of the year 
over 2 consecutive years were described as exacerbators 
with chronic bronchitis, and 4) the remaining exacerbators 
were classified as exacerbators without chronic bronchitis 
(predominantly with emphysema).29
Analytical methods
Categorical variables were described by absolute and rela-
tive values. Median supplemented by the 5th–95th percentile 
range was used for continuous variables; a valid N was 
Table 3 POPE study – captured parameters
Form Parameter
History Demographic data
Age of first diagnosis
History of allergy/atopy
COPD symptoms
Smoking history
Other than tobacco smoking risk factorsa
History of acute respiratory events
Concomitant respiratory diseases
Weight assessment
Comorbidities – Charlson comorbidity index
Comorbidities – others
Physical examination BMI
Heart and breath frequency
Physical signs of COPD and heart failure sings
Pulmonary function  
tests, laboratory
Postbronchodilator spirometry values
Body plethysmography (tlC and rV)b
tlCO and KCO
b
Bronchodilator testb
Bronchial challenge testb
FeNOb
HrCt of thoraxb
Echocardiographyb
Blood/sputum eosinophil assessmentb
6-minute walk testb
total serum IgE measurementb
ABGb
HCtb
Questionnaires CAt (total score and all 8 items separately)
mMrC
treatment COPD pharmacological and  
nonpharmacological treatment
Other respiratory treatment
ltOt
Surgery and BVr
Vaccination
Nonrespiratory concomitant treatment
Notes: arequired in nonsmokers, boptional.
Abbreviations: ABG, arterial blood gas; BMI, body mass index; BVr, 
bronchoscopic lung volume reduction; CAt, the COPD assessment test; 
COPD, chronic obstructive pulmonary disease; FeNO, fractional exhaled nitric 
oxide; HCt, hematocrit; HrCt, high-resolution computed tomography; IgE, 
immunoglobulin E; KCO, Krogh factor; ltOt, long-term oxygen therapy; mMrC, 
modified Medical Research Council dyspnea scale; RV, residual volume; TLC, total 
lung capacity; tlCO, transfer factor.
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reported in the case of missing values in continuous variables. 
Mean supplemented by standard deviation or 95% confi-
dence interval was adopted for continuous variables when 
normality of the data was proven. Statistical significance of 
differences in continuous variables between/among groups 
of patients was analyzed using the Mann–Whitney U-test and 
Kruskal Wallis test, and Student’s t-test for two groups or 
analysis of variance (ANOVA) followed by Tukey post hoc 
test. Paired t-test and/or the Wilcoxon paired test was used 
to analyze the statistical significance of differences of con-
tinuous variables between study time points; the McNemar 
test was used for the same purpose for categorical variables. 
Factors influencing binary end points without time to event 
and censoring (1 year mortality, etc) were analyzed using 
logistic regression. α=0.05 was used as a level of statistical 
significance. Analyses were performed using SPSS 22.0.0 
(IBM Corporation, Armonk, NY, USA, 2013).
Sample size calculation
The background information from the available literature 
regarding the proportion of patients in different GOLD 
categories and occurrence of COPD phenotypes was utilized 
in the power analysis prior to the study.9,10,30 The aim of the 
power analysis was to determine the sample size required to 
detect statistically significant differences in the prevalence of 
COPD phenotypes and other classification groups of interest, 
such as GOLD (1–4) and GOLD (A–D) measured as relative 
risk (RR) between participating countries within POPE study. 
Power analysis revealed that the optimal number of patients 
from the CEE region should be 3,500. This total number 
enables the observation of differences between various 
countries or groups of countries within the entire CEE region 
(sufficient precision guaranteed: approximately ±4% or ±2% 
within each participating country with categories/phenotypes 
of 20% or 5% prevalence, respectively; detectable RR of 
categories/phenotypes of 20% prevalence at least 1.5; detect-
able RR of categories of 5% prevalence nearly 2.0). Finally, 
we estimated a prevalence of nonsmoking subjects in approxi-
mately 5%–10% of the CEE COPD population.31,32
Organization of the study
The POPE study was an investigator-initiated study by a 
group of COPD researchers predominantly from CEE coun-
tries who recently formed a research forum called the “COPD 
Platform”. This study was managed and supervised by the 
Steering Committee, which was responsible for the design 
and scientific integrity of the study (Table 2). The project 
management and statistical background was provided by the 
Institute of Biostatistics and Analyses, Masaryk University 
(Brno, Czech Republic). Data in the POPE study were entered 
into a database system, which was originally based on a modi-
fied version of the TrialDB system.33–35 The TrialDB system 
is an easy and accessible tool for parametric data collection, 
validation, statistical processing, and online data management 
in compliance with respective legislation. A similar design 
was used in the multicenter, observational, cross-sectional 
PUMA study performed in Argentina, Colombia, Uruguay, 
and Venezuela.36 The online application is accessible to 
users via the Internet browser. The security of individual 
records within the registry is ensured via deidentified data 
collection. An encryption protocol is used for data transfer 
between the user and central database to prevent tapping 
the communication between the client and server. For this 
reason, any communication between the client and server 
is achieved via the secure protocol HyperText Transfer 
Protocol Secure, using Secure Socket Layer encryption. The 
security of individual records within the registry is ensured 
via deidentified data collection.
The POPE study was registered in ClinicalTrials.gov 
with the identifier NCT02119494. More information can 
be obtained at http://www.copdplatform.com/. The sponsor 
of the study is the Ludwig Boltzmann Institute for COPD 
and Respiratory Epidemiology, Vienna, Austria. The 
research institute received an unrestricted research grant 
from Boehringer Ingelheim RCV GmbH & Co. KG, which 
provided partial support for this study but had no influence 
on the rationale, methodology, or analysis.
Ethics
This study was performed in accordance with the European 
Union laws and the respective laws of participating countries. 
The study, protocol, informed consent, and patient informa-
tion were submitted to ethic committees in the respective 
countries and to regulatory agencies, where required. The 
rights, safety, and well-being of clinical investigation sub-
jects were protected according to the ethical principles of the 
Declaration of Helsinki. All patients (except Poland, where 
Ethic Committee approval was not required) were requested 
to provide their informed consent.
Discussion
Phenotyping patients with COPD has received increasing 
awareness in recent years.37–41 A phenotype is defined as 
“a single or combination of disease attributes that describe 
differences between individuals with COPD as they relate to 
clinically meaningful outcomes”.37 A phenotypic approach 
to classify COPD has been adopted by a number of national 
and international societies.9,29,42–44 It is actively used by the 
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Czech and Spanish COPD guidelines to promote treatment 
tailored to disease presentation, beyond singular treatment 
of airflow obstruction.42,43 However, there is no general 
consensus on the number of phenotypes and the precise 
definition. Furthermore, we may need to acknowledge that 
individual patients may qualify for more than one pheno-
type.42 A recent Spanish guideline proposed a classification 
of patients with COPD according to phenotypes similar to 
those used in the POPE study: infrequent exacerbators, fre-
quent exacerbators with emphysema, frequent exacerbators 
with chronic bronchitis predominance, and the ACOS.29,43 
The definition of ACOS remains controversial; however, 
it may include the presence of COPD with either allergic 
rhinitis, bronchial hyperresponsiveness, and/or a previous 
diagnosis of asthma with reversible airflow obstruction.45 The 
four (aforementioned) elementary COPD phenotypes used 
in the POPE study were based on routine clinical practice 
as they have some treatment consequences. Undoubtedly, 
wide scope of gathered parameters allows to evaluate the 
presence of COPD subjects with other disease “phenotypes”, 
for example, COPD with pulmonary cachexia, COPD with 
high burden of comorbidities. Using these patient profiles in a 
recently published, observational, multicenter study of 3,125 
patients with COPD, Miravitlles et al28 observed a distribu-
tion of 60% nonexacerbators, 18% patients with ACOS, 19% 
exacerbators with chronic bronchitis, and 4% exacerbators 
without chronic bronchitis. While ACOS patients were more 
frequently females with better lung function, exacerbators 
presented with the most severe disease, with little difference 
between those with and without chronic bronchitis.
What is the clinical relevance of 
phenotyping patients with COPD?
First, there is evidence of differences in outcomes between 
different phenotypes. Burgel et al46 observed significant 
differences in mortality when stratifying patients into 
phenotypes on the basis of airflow obstruction, evidence 
of emphysema, body mass index, and comorbidities. 
Using a very comprehensive and in-depth assessment 
of 342 patients with COPD, including symptoms, quality 
of life, exercise capacity, nutritional status, biomarkers of 
systemic and bronchial inflammation, sputum microbiology, 
computed tomography of the thorax, and echocardiography 
in addition lung function, Garcia-Aymerich et al47 similarly 
demonstrated substantial differences in hospitalization rates 
and all-cause mortality between patient clusters. Second, 
there is increasing recognition and clinical acceptance to 
treat patients according to their phenotypic predominance. 
Infrequent exacerbators, defined as patients experiencing ,2 
exacerbations per year, may be treated with bronchodilation 
alone, and withdrawal of inhaled glucocorticoids may be safe 
in this particular population, according to data from recent 
studies.48,49 Patients with COPD and a diagnosis of asthma may 
in turn have a survival benefit when treated with inhaled cor-
ticosteroids.50 Similarly, augmented anti-inflammatory treat-
ment, such as Roflumilast, may only improve excarbation rates 
in patients with chronic bronchitis and frequent exacerbations, 
whereas in patients with emphysema, there is no therapeutic 
benefit.51 The POPE study furthermore investigated whether 
patients received nonpharmacological treatments in the past, 
such as long-term oxygen therapy, noninvasive ventilation, or 
lung volume reduction procedures (surgical or endoscopic).
Why performing a study of COPD 
phenotypes in CEE?
Many previous studies have attempted to identify and quan-
tify the prevalence of different phenotypes of COPD using 
populations of various sources, severities, and particularities. 
The health care system, however, may substantially differ 
in CEE compared with other systems around the globe. 
Differences in environmental pollution, smoking prevalence, 
and comorbidities may substantially contribute to differences 
in the level of burden of COPD across the CEE region.52,53 
The POPE study specifically investigated symptom load, 
comorbidities, lung function, and exacerbation rates in both 
smoking and never-smoking patients with COPD in CEE 
and compared the results between these two groups. In fact, 
the prevalence of COPD in lifelong nonsmoking subjects 
in Poland was found to be 12%, whereas the prevalence of 
COPD in the nonsmoking population from Western countries 
usually ranged between 2% and 4%.31,32 These differences 
may potentially be due to differences in mean fine particu-
late matter (PM
2.5
) concentrations in CEE compared with 
Western Europe.54 Moreover, different risks could lead to 
different clinical presentation of COPD syndrome. COPD 
of nonsmoking females due to biomass smoke exposure for 
instance is characterized by less emphysema but more air 
trapping than COPD due to tobacco smoke exposure.55 On the 
other hand, access to modern therapeutic modalities due to 
differences in copayment may be different between Western 
and Eastern European countries, thus affecting prescribing 
behavior.56 The POPE study shed new light onto the thera-
peutic relevance of phenotypes in a real-life setting in CEE. 
The multinational and multicenter approach in the POPE 
study was chosen not only to describe the status of patient 
care across the CEE region but also within the individual 
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participating countries. Finally, in contrast to many Western 
European countries where patients with COPD are mostly 
under the long-term supervising care of general practitioners, 
in CEE countries, these patients are rather taken care of by 
respiratory specialists (Table 4).30,42,57–59
Limitations
The POPE study design has a number of limitations that need 
to be acknowledged. First, it is a purely cross-sectional study 
aimed at assessing the prevalence of predefined phenotypes, 
without being able to validate these phenotypes prospectively 
on the basis of outcomes. Nevertheless, eligible patients under-
went pre- and postbronchodilator spirometry, and completed 
a standardized questionnaire on demographics, environmental 
risk factors, symptoms, comorbidities, management, and use 
of health care resources.36 The information provided through 
this comprehensive assessment is novel for the CEE region. 
Second, the POPE study was performed in multiple centers 
with different levels of health care access and differences in 
diagnostic and therapeutic approaches. Lung function assess-
ment was performed in accordance with international guide-
lines, but without further standardizations or core laboratory 
evaluations. Thus, we cannot rule out differences in quality 
measures of performing these and other tests that might 
impact the comparability between sites and between coun-
tries. Nevertheless, the information provided in this context 
might also be considered the strength of the POPE study, as it 
provides real-life data regarding important information about 
the diagnostic approach and treatment modalities of patients 
with COPD in CEE.
Conclusion
The POPE provides new data regarding symptoms, clini-
cal presentation, and treatment modalities of patients with 
COPD observed in daily clinical practice in the CEE region. 
This study may further prompt future research collaborations 
within participating countries with the intention to answer 
a number of other important unaddressed questions, such 
as the natural course of phenotypes, real-life prescription 
behavior in treatment-naive patients, and/or regional dif-
ferences in treatment adherence. The long-term aims of the 
POPE study, however, are to educate and raise awareness 
for phenotypes of COPD and its potential implications 
regarding treatment and outcomes among both physicians 
and patients.
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